Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377990 | 0.96 | PIK3CA (0.58) | PIK3CAPIK3R1HPGDSMN1; SMN2PIK3CB | |
| SCHEMBL2376861 | 0.93 | PIK3CA (0.58) | PIK3CAPIK3R1HPGDSMN1; SMN2PIK3CB | |
| SCHEMBL2377804 | 0.93 | PIK3CA (0.58) | PIK3CAPIK3R1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL2378960 | 0.92 | PIK3CA (0.63) | PIK3CAPIK3R1HPGDSMN1; SMN2PIK3CB | |
| SCHEMBL2378154 | 0.92 | PIK3CA (0.59) | PIK3CAPIK3R1HPGDSMN1; SMN2 | |
| SCHEMBL2377595 | 0.92 | PIK3CA (0.58) | PIK3CAPIK3R1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL2378262 | 0.91 | PIK3CA (0.58) | PIK3CAPIK3R1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL2376624 | 0.90 | PIK3CA (0.61) | PIK3CAPIK3R1PIK3CB | |
| SCHEMBL2379592 | 0.90 | PIK3CA (0.60) | PIK3CAPIK3R1PIK3CB | |
| SCHEMBL2378729 | 0.90 | PIK3CA (0.57) | PIK3CAPIK3R1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | PIK3CA 1/4885PIK3R1 5/4885HPGD 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.